Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 16 Feb 2023
As more states repeal or restrict abortion laws, the number of patients, the number of workers needed, and the cost of heart disease will increase. How should hospitals and policy makers prepare?
Read Full NewsNon-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care
Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents
Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk
Frontline Decisions in Transplant-Ineligible Multiple Myeloma: Evaluating Quadruplet Therapy
1.
A pilot study investigates a novel strategy for lowering anxiety and enhancing post-stem cell transplant quality of life.
2.
Weight-Based and Fixed-Dose Pembrolizumab Compared in NSCLC
3.
Significant worldwide disparities seen in availability and timeliness of new cancer drugs
4.
CAR-T Trial Raises Prospect of Preventing Myeloma in High-Risk Group
5.
Report reveals lung cancer is the leading cause of cancer deaths in Florida
1.
AI Meets the Gut Microbiome: Early Detection of GI Malignancies Redefined
2.
Unlocking the Mystery of Methaemoglobinaemia: A New Hope for Treatment
3.
How AI, Multi-Omics, and Real-World Evidence are Redefining Oncology Research and Shaping Cancer Care?
4.
Understanding Mesenteric Masses: Symptoms, Diagnosis, and Treatment Options
5.
A Review on Genetic Predispositions and Clinical Advancements of Multiple Myeloma Cancer
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
3.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
4.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
5.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge